

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

MYLAN PHARMACEUTICALS INC.,

Plaintiff, v.

TEVA PHARMACEUTICALS
INDUSTRIES LTD, TEVA
PHARMACEUTICALS USA, INC., TEVA
NEUROSCIENCE, INC., AND TEVA
SALES & MARKETING, INC.,

Defendants.

Civil Action No. 21-13087 (JXN) (JSA)

In re: COPAXONE ANTITRUST
LITIGATION

Master Docket No. 22-1232 (JXN) (JSA)

(Coordinated for Discovery Purposes Only)

This documents relates to: All Actions

ORDER

THIS MATTER having come before the Court by way of the parties' joint status letter filed on November 18, 2024, wherein the parties set forth their scheduling disputes in *Mylan Pharms. Inc. v. Teva Pharms. Indus. Ltd.*, Civ. No. 21-13087 (JXN) (JSA) ("*Mylan Action*"), (ECF No. 154), and in *In re: Copaxone Antitrust Lit.*, Civ. No. 22-1232 (JXN) (JSA) ("*In re Copaxone Matter*"), (ECF No. 122);

and it appearing that the court-appointed Special Master, the Honorable Faith S. Hochberg U.S.D.J. (Ret.), issued a Report and Recommendation dated November 25, 2024, in which Judge Hochberg recommended a specific case schedule, (*see* Report and Recommendation, at 5–6);

and it appearing that neither Defendants nor Plaintiffs have filed any objections to the Report and Recommendation; and

it appearing that for the reasons set forth in Judge Hochberg's Report and Recommendation;

IT IS on this 19th day of December, 2024,

ORDERED that Judge Hochberg's Report and Recommendation dated November 25, 2024, is **ADOPTED**.

/s/ Jessica S. Allen

HON. JESSICA S. ALLEN
United States Magistrate Judge

cc: Hon. Julien Xavier Neals, U.S.D.J.